Please enter your details to request more information

Your Gateway to the Booming Medicinal Cannabis Market

Crucial Innovations Corp

The Medicinal cannabis market is expected to grow at (CAGR) 12.47% between 2024-2028

Discounted Share Offer: Invest at 50 cents per share (valued at $1)

Market Insights:

• Global Sales: Forecasts indicate global sales of medicinal cannabis to reach $1.37 billion by 2027, reflecting a rapidly expanding market.*
• Industry Interest: Major players like Jazz Pharmaceuticals and Pfizer have made billion-dollar acquisitions, underscoring the immense interest from industry giants.
• Global Legalisation: With over 60 countries legalising some form of medicinal or recreational cannabis, the market is ripe for exponential growth.
  

Investment Highlights:

• Already on the OTC market, CINV is poised for growth with plans for NYSE/NASDAQ uplisting in 18 months.
• Anticipate first harvest in April 2024 and revenue generation by the end of Q2 2024.
• Estimate company revenue to reach $178 million by 2028.**
• Several confirmed joint ventures including licensed clinics, processing facilities, and distribution partners, to ensure a complete seed-to-heal journey.
• A robust sales pipeline is in place, ensuring sustained growth and market penetration.
• By Q2 2024, CINV aims to introduce a B2C medical cannabis brand, tapping into the rising demand for premium products delivering the full entourage effect.

Introducing Ember Pharms:

• State-of-the-Art Facility: Ember Pharms, is a wholly-owned subsidiary of CINV, operates a cutting-edge cultivation, drying, and processing facility in South Africa. Spanning 17,000 sqm of owned land, Ember Pharms is poised to become the leading EU-GMP-certified extraction facility in South Africa, ensuring unparalleled quality and compliance.
  
• Capacity: Annual capacity of 2200kg - 3000kg once fully operational with both greenhouse and indoor grows
  
• Strategic Advantage: Located in South Africa, Ember Pharms benefits from optimal growing conditions and cost-effective operations, positioning CINV for sustained success in the global market.
  

About

CINV is a licensed organic medicine company leading the way in medicinal cannabis and psilocybin cultivation. We leverage award-winning techniques to produce premium cultivars renowned for their taste and quality.

• Global Reach: Our strategic partnerships and operational footprint span South Africa and Europe, allowing us to navigate the complexities of the international cannabis market.
• At CINV, we believe in the power of organic medicine to transform lives. Through our integrated network of cultivation, distribution, and care, we are dedicated to improving patient outcomes and advancing the future of healthcare.

Invest in CINV today and be part of a transformative journey in the medicinal cannabis industry. Don't miss your chance to capitalise on this lucrative investment opportunity.

Lawyer

Denos Law

Reporting Accountant

Pub Co Reporting

Corporate Governance

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to us contacting you via these methods. Privacy policy

Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.